Compare Novo Nordisk A/S (NVO) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Snap Inc — how do they compare? Novo Nordisk A/S trades at $44.72 (market cap $200.69B), while Snap Inc trades at $5.31 (market cap $9.18B). The key difference: Novo Nordisk A/S is far larger — about 21.9× Snap Inc's market cap, and Novo Nordisk A/S pays a 3.98% dividend while Snap Inc pays none. Which is the better fit depends on your goals.
| NVO | SNAP | |
|---|---|---|
Market Cap | $200.69B | $9.18B |
Sector | Health | Media |
52-Week High | $63.98 | $9.09 |
52-Week Low | $35.29 | $3.93 |
Enterprise Value | $215.49B | $10.75B |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Snap Inc. (SNAP) trades at $5.43, down 0.73% with a bullish technical signal despite recent legal pressures. The company shows improving fundamentals with revenue growth to $5.93B in 2025 and narrowing losses (-$460M net income). Analyst consensus is mixed with 38% buy ratings and a $7.02 price target, while recent news highlights leadership changes and ongoing youth-safety lawsuits.
Snap presents a turnaround story with operational improvements but faces significant legal and competitive risks. The stock offers potential upside to analyst targets if execution continues, though persistent losses and regulatory challenges warrant caution for investors seeking stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
